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Growth hormone (GH) secretion, either spontaneous or evoked by provocative stimuli, is markedly blunted in obesity.
In fact obese patients display, compared to normal weight subjects, a reduced half-life, frequency of secretory
episodes and daily production rate of the hormone. Furthermore, in these patients GH secretion is impaired in
response to all traditional pharmacological stimuli acting at the hypothalamus (insulin-induced hypoglycaemia,
arginine, galanin, L-dopa, clonidine, acute glucocorticoid administration) and to direct somatotrope stimulation by
exogenous growth hormone releasing hormone (GHRH). Compounds thought to inhibit hypothalamic somatostatin
(SRIH) release (pyridostigmine, arginine, galanin, atenolol) consistently improve, though do not normalize, the
somatotropin response to GHRH in obesity. The synthetic growth hormone releasing peptides (GHRPs) GHRP-6
and hexarelin elicit in obese patients GH responses greater than those evoked by GHRH, but still lower than those
observed in lean subjects. The combined administration of GHRH and GHRP-6 represents the most powerful GH
releasing stimulus known in obesity, but once again it is less effective in these patients than in lean subjects. As for
the peripheral limb of the GH ± insulin-like growth factor I (IGF-I) axis, high free IGF-I, low IGF-binding proteins 1
(IGFBP-1) and 2 (IGFBP-2), normal or high IGFBP-3 and increased GH binding protein (GHBP) circulating levels have
been described in obesity. Recent evidence suggests that leptin, the product of adipocyte speci®c ob gene, exerts a
stimulating effect on GH release in rodents; should the same hold true in man, the coexistence of high leptin and low
GH serum levels in human obesity would ®t in well with the concept of a leptin resistance in this condition.
Concerning the in¯uence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia
and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in obese patients;
furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) signi®cantly improve
somatotropin secretion in obesity. Caloric restriction and weight loss are followed by the restoration of a normal
spontaneous and stimulated GH release. On the whole, hypothalamic, pituitary and peripheral factors appear to be
involved in the GH hyposecretion of obesity. A SRIH hypertone, a GHRH de®ciency or a functional failure of the
somatotrope have been proposed as contributing factors. A lack of the putative endogenous ligand for GHRP
receptors is another challenging hypothesis. On the peripheral side, the elevated plasma levels of NEFA and free
IGF-I may play a major role. Whatever the cause, the defect of GH secretion in obesity appears to be of secondary,
probably adaptive, nature since it is completely reversed by the normalization of body weight. In spite of this,
treatment with biosynthetic GH has been shown to improve the body composition and the metabolic ef®cacy of lean
body mass in obese patients undergoing therapeutic severe caloric restriction. GH and conceivably GHRPs might
therefore have a place in the therapy of obesity.
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Introduction
Obesity, defined as an increased amount of body fat1
and estimated by different techniques, is a chronic
clinical condition, since no successful treatment is
available at the present time. In recent years there has
been a growing awareness that obesity is a serious
health problem because of its high prevalence and
increasing incidence.2 Great efforts are now being
made to extend the knowledge of this condition and
to develop efficacious therapies.
Growth hormone (GH) is endowed with remarkable
metabolic (chiefly protidoanabolic and lypolitic)
effects and its secretion is, for still undefined reasons,
greatly reduced in obese subjects. However, a pro-
gressive increase in the hormonal secretion is
observed with the reduction of body weight. GH
secretion is chiefly controlled by the hypothalamus
through the stimulating action of growth hormone
releasing hormone (GHRH) and the inhibiting influ-
ence of somatostatin (SRIH), which are in turn
switched off and on, respectively, by the pituitary
hormone. This functional loop is modulated by central
(neurotransmitters and neuropeptides) and peripheral
factors. Among the latter, a pivotal role is played by
the negative feedback exerted by insulin-like growth
factor I (IGF-I), the mediator of most GH biological
actions, and by a number of metabolic and nutritional
signals influencing the GH-IGF I axis. The present
review will focus on the main pathophysiological
aspects of the deranged somatotropin release observed
in obese patients. These abnormalities involve both
spontaneous and stimulated GH secretion, as well as
the peripheral limb of the axis.
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Spontaneous GH secretion
The application of computerized algorithms to the
study of spontaneous GH release allowed to define
the characteristics of secretory episodes (frequency,
duration, amplitude, interpulse hormonal values) and,
by means of deconvolution analysis, to gain informa-
tion on the production rate and the metabolic clear-
ance of the hormone.
In recent years, several studies of normal subjects
have established strong relationships between para-
meters of spontaneous somatotropin secretion and
variables such as age, fitness and degree of adiposity.
In particular, negative correlations were established
between body mass index (BMI) on one side and GH
half-life, amplitude of GH secretory episodes3 and the
pulsatile component of GH release4 on the other side.
Furthermore, the percentage of body fat was nega-
tively correlated with 24 h GH integrated concentra-
tion,4,5 GH amount per secretory burst and GH half-
life.4
In agreement with these findings, an impairment of
spontaneous somatotropin secretion is well documen-
ted in obese patients, who, compared to normal weight
subjects, display reduced GH half-life, frequency of
GH secretory episodes and daily GH production rate.6
The amount of GH released per burst and the duration
of secretory episodes are on the contrary comparable
in obese and lean subjects. Thus, the hyposomatotro-
pinism of obesity appears to be accounted for by at
least two main abnormalities, that is, a dramatic
impairment of GH production (about 4-fold lower
than that described in normal subjects) and a signifi-
cant reduction of GH half-life (about 11 min, com-
pared to 15 min measured in normal weight
volunteers). Both these alterations are positively cor-
related with the degree of excess weight. In particular,
daily GH secretion rate and production rate have been
calculated to fall by 6% for each unit increase in BMI,
and 50% for an increase in BMI from 21 kg=m2 to
28 kg=m2 respectively.3
In line with the impaired spontaneous GH release
documented in obesity, the urinary excretion of the
hormone is markedly reduced in obese children, with




In obesity, GH secretion is impaired in response to all
traditional pharmacological stimuli acting at the
hypothalamus. Significantly blunted hormonal
responses have been reported after insulin-induced
hypoglycaemia,9 – 11 i.v. infusion of arginine12 and
galanin,13 oral administration of L-dopa14 and
clonidine,12 i.v. administration of a met-enkephalin
analogue11 and of several corticosteroids.15,16 An
impaired GH responsiveness to physiological chal-
lenges such as physical exercise and sleep is also well
documented in obese patients.17,18
Pharmacological manipulations of the central neuro-
transmitter systems are capable of modifying, in obese
as in lean subjects, the somatotropin response to some
of these suprapituitary stimuli. Administration of
pyridostigmine, a cholinesterase inhibitor acting as
an indirect cholinergic agonist, improves the GH
response to L-dopa,14 clonidine and arginine.12 An
improvement in the hormonal response to arginine
and insulin-induced hypoglycaemia has been shown
after oral administration of the indirect serotonin
agonist fenfluramine.19,20 Finally, the opiate antago-
nist naloxone is also capable of increasing the GH
response to arginine in obese patients.21
GHRH
In overweight subjects, a blunted GH rise has con-
sistently been described in response to direct somato-
trope stimulation by exogenous GHRH, given either
as i.v. bolus22 or as pulsatile23 or continuous24 i.v.
infusion. Not even the pre-treatment with GHRH itself
(1mg=kg daily as an i.v. bolus for eight consecutive
days) is able to increase the somatotropin response to
its subsequent application.25 On the contrary, the
hormonal response to the releasing hormone is
improved by long-term oral administration of the
opiate antagonist naltrexone.26
Although unable per se to evoke a significant GH
rise in obese subjects,27 the cholinergic indirect ago-
nist pyridostigmine, like other compounds likely to be
acting via inhibition of hypothalamic SRIH release
(arginine, galanin and the beta-blocking agent ateno-
lol), consistently improves the GH response to
GHRH.13,28 – 33 Although enhanced, however, this
reponse is not normalized remaining superimposable
to that evoked in normal weight volunteers by GHRH
alone and well below the one registered in these latter
after the combined stimulus. Of note, in 50% of obese
patients the magnitude of GH rise following combined
administration of GHRH and arginine overlaps with
that displayed by adults with organic GH deficiency
after the same stimulus.34
Personal data regarding the GH responsiveness to
clonidine and to GHRH pyridostigmine in obese
patients at baseline and after weight loss are shown
in Figure 1.
GH releasing peptides (GHRPs)
GHRPs are small synthetic peptides, structurally
related to metenkephalin, endowed with a potent
GH-releasing effect, greater than that of GHRH.35
They appear to exert their action both at hypothalamic
and pituitary level, interacting with receptors for a
putative endogenous ligand, which are unrelated to
enkephalin, SRIH and GHRH receptors. Additionally,
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GHRPs appear to act as functional SRIH antagonists
through post-receptor mechanisms.35
In obese patients, these peptides, and in particular
GHRP-6 and hexarelin, elicit GH responses greater
than those evoked by GHRH, but still lower than those
evoked in lean subjects.36 – 38 The same holds true for
the nonpeptide mimetic of GHRP L-692,429.39
Furthermore, the combined administration of GHRH
and GHRP-6 represents the most powerful GH-releas-
ing stimulus known in obesity (mean peak higher than
40mg=l) though once again less effective in these
patients than in normal weight subjects (mean peak
higher than 75mg=l).40 In both normal and obese
subjects, the GH response to combined administration
of GHRH and GHRP-6 is not modified by the pyr-
idostigmine-induced reduction of central SRIH tone.40
Peripheral limb of the GH-IGF-I axis
The evaluation of total IGF-I serum levels in obese
patients has yielded conflicting results. Normal,41 – 43
low44 – 46 or high47 – 49 serum concentrations of the
growth factor have been described. Studies on
selected series of obese patients have shown that
low IGF-I levels tend to be present in patients with
abdominal obesity, a condition associated with higher
serum concentrations of non esterified fatty acids
(NEFA): in these studies negative correlations were
found between IGF-I levels and the amount of visceral
fat.50,51 On the other hand, measurements of the free
fraction of IGF-I have recently allowed to demon-
strate higher serum levels of this parameter in obese
patients compared to lean subjects.42,43,46 This is
probably due to the well documented reduction of
IGF-binding proteins 1 (IGFBP-1) and 2 (IGFBP-
2),42,43,46,52 whose production is physiologically inhib-
ited by insulin, generally increased in overweight
subjects. The greater availability of free, biologically
active IGF-I, might explain the normal growth of
obese children in spite of markedly impaired GH
secretion. Furthermore, contrary than in primary GH
deficiency where IGFBP-3 levels are low, the
hyposomatotropinism of obesity appears to be asso-
ciated with normal43 or high46 IGFBP-3 serum con-
centrations. A positive correlation between IGFBP-3
and free IGF-I levels has been shown in obese
children.46
Abundant IGF-I mRNA and IGF-I peptide levels
have been found in rat white adipose tissue (WAT).53
Figure 1 Upperpanel. Growth hormone (GH) response to clonidine stimulation (Catapresan, Boehringer, Florence, Italy, 2mg=kg e.v.)
in six normal weight controls -j- (BMI 22.80.28 kg=m2), 13 obese patients -- (body mass index, BMI 411.15 kg=m2), and eight of the
previous patients after weight loss -m- (BMI 30.52.56 kg=m2). On the right side the corresponding areas under the curve (AUC) are
reported. (Controls u, obese j; obese after weight loss .) Bottom panel. GH response to GH releasing hormone (GHRH)pyrido-
stigmine stimulation (GHRH, Sano®, Paris, France, 1mg=kg e.v. at time 0, and Mestinon, Roche, Basel, Switzerland, 120 mg per os
30 min before GHRH injection) in the same subjects on the right side of the corresponding AUCs. aP<0.05 obese patients vs normal
weight controls; bP< 0.05 obese patients vs themselves after weight loss; *P<0.05.
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In particular, IGF-I mRNA concentrations in WAT
were comparable to those found in the liver,53 the
major source of circulating IGF-I.54 IGF-I mRNA and
IGF-I peptide levels in WAT are regulated by GH,53
through specific receptors on adipocytes.55 It appears
unlikely, however, that IGF-I from WAT contributes
to the circulating IGF-I concentrations, and hence to
the control of GH release. In fact, WAT does not
release in vitro substantial amounts of IGF-I,53 while
the secretion rate of IGF-I from isolated rat livers fully
accounts for the serum IGF-I levels normally found.54
WAT IGF-I probably acts locally in an autocrine=
paracrine manner. As IGF actions are modified by
IGFBPs, the local production of these latter could
have a major impact on the autocrine=paracrine mode
of IGF action. Rat WAT expresses the messages for
IGFBP-2, -3, -4, -5, and -653,56; IGFBP-2,-3,-5, and -6
mRNAs are all regulated by GH.53,56 WAT IGFBPs
can be assumed to bind a major portion of the IGF-I
synthesized in this tissue, probably inhibiting its acute
insulin-like effects on adipocytes57 mediated via insu-
lin receptors.58 Locally produced IGFBPs may retain
IGF-I at the site of synthesis or extract the peptide
from the circulation, thereby providing a local IGF
reservoir. IGF-I produced in WAT under the influence
of GH may also play a critical role in adipocyte
differentiation. Despite binding of IGF-I to IGFBPs,
the free IGF-I in the interstitial fluid of WAT may still
be high enough to allow interaction with the type I
IGF receptor on adipose precursor cells and trigger
their differentiation.
Increased circulating levels of the high affinity GH
binding protein (GHBP), corresponding to the extra-
cellular domain of the GH receptor, have been
described in obese patients41,46,49,59 with positive
correlations between serum levels of this molecule
and both BMI49 and percent body fat mass.59 Finally,
a decreased binding of IGF-I to its receptor has been
reported in obesity.49 Thus, when considering the
elevated serum levels of GHBP and the reduced
number of IGF-I receptors, obesity may be seen as a
condition characterized by increased sensitivity to GH
and resistance to IGF-I. The opposite pattern, that is,
low GHBP concentrations and high IGF-I binding, has
been described in a condition of malnourishment such
as anorexia nervosa49 (Table 1).
Leptin as a peripheral signal for GH
regulation
Leptin, the protein encoded by the recently discov-
ered adipocyte specific ob gene, is presently assigned
a critical role in the regulation of body weight.60,61
This function is chiefly accomplished by decreasing
food consumption,62,63 an effect probably mediated
through inhibition of neuropeptide Y (NPY) secre-
tion64 – 66 and enhancement of energy expenditure.67,68
Indeed, serum leptin levels are elevated in simple
obesity69 and in clinical conditions associated with
increased body fat such as Cushing’s syndrome70 and
adult GH deficiency,71,72 and low in anorexia ner-
vosa.73,74 On the other side, GH also takes part in the
regulation of body composition through a marked
nitrogen sparing and lipolytic effect,75 as shown by
its administration to obese76 and GH deficient
patients.77 Therefore, the existence of a GH-leptin
interaction is not surprising. In vitro, neither GH nor
IGF-I are able to affect leptin release from isolated rat
adipocytes.78 In vivo, GH replacement therapy has
been shown to normalize the basally elevated leptin
levels of GH deficient adults,71,72 but this effect is
probably secondary to the fat-mass-reducing action of
the hormone. Regarding the influence of leptin on GH
secretion, i.c.v. injection of leptin antiserum to fed
rats led to a decrease in spontaneous GH release,
while i.c.v. administration of leptin to fasted rats was
followed by a reversal of the fasting-induced suppres-
sion of GH secretion.79 This stimulatory effect of
leptin on GH release appears to be mediated by both
GHRH and SRIH at hypothalamic level. In vivo, i.c.v.
leptin administration to fasted rats prevented the
inhibitory effect exerted by fasting on GHRH
mRNA levels in the arcuate nuclei, while administra-
tion of GHRH antiserum abolished leptin-induced GH
secretion. On the contrary, administration of SRIH
antiserum, increased leptin-induced GH secretion in
fasted rats.80 In vitro, incubation of rat hypothalamic
neurons with leptin led to a time dependent decrease
in basal SRIH secretion and SRIH mRNA levels, the
maximal effect being observed after 24 h.81 Leptin
also inhibited the hypoglycaemia-induced release of
SRIH from perifused adult rat hypothalami after a
short-term exposure.81 In all likelihood, the leptin
regulation of GH release, as described above, is
mediated by inhibition of NPY secretion, since
i.c.v. NPY injection has been shown to prevent
leptin-induced GH release in fasted rats.80 Further-
more, the exposure of rat hypothalamic neurons to
leptin, prevented the stimulatory effect elicited by
NPY on SRIH mRNA levels and SRIH secretion.81
Interestingly, SRIH seems capable of regulating
leptin secretion. In fact, SRIH infusion in normal
weight humans induced a 19% decrease of circulating
leptin levels over the first 120 min.82 Assuming that
the GH regulation by leptin in man is the same as in
the rat, leptin, by favouring GH secretion, might
reinforce its own biological effects, chiefly directed
(as far as we presently know) at regulating the body
fat content. On the other side, the coexistence of high
leptin and low GH serum levels in obesity fits in well
with the concept of a leptin resistance in this
condition.
Table 1 Growth hormone (GH) and insulin-like growth factor I
(IGF-I) sensitivity in weight disorders
Obesity  increased GH
sensitivity
 IGF-I resistance
Anorexia nervosa  GH resistance  increased IGF-I
sensitivity
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Metabolic and nutritional factors
Glucose
An impaired GH response to hypoglycaemia is well
documented in obesity.9 – 11 Moreover, recent studies
performed with hyperglycaemic clamp and oral glu-
cose load have demonstrated that in obese patients,
contrary to normal subjects, hyperglycaemia does not
inhibit spontaneous83 and stimulated (GHRH, argi-
nine, hexarelin)38,84 GH secretion. On the contrary,
the somatotropin response to GHRH and arginine is
physiologically blunted by administration of SRIH and
of the cholinergic antagonist pirenzepine.84 These
observations suggest an inability of hyper-glycaemia
to trigger hypothalamic SRIH release in obesity.
Insulin
Obesity is characterized by fasting hyperinsulinemia
and exaggerated insulin release in response to a mixed
meal or a glucose load.85,86
Experimental data support the existence of a nega-
tive feedback exerted by circulating insulin on GH
secretion. In normal subjects, a progressive reduction
of the GH response to hypoglycaemia87 and GHRH88
has been observed with increasing insulin concentra-
tions.
The mechanisms whereby insulin regulates GH
release are not completely clarified yet. Insulin
might act at both the hypothalamic and the pituitary
level via its multiple metabolic pathways. By binding
to specific hypothalamic receptors,89 – 91 insulin could
enhance the release of catecholamines,92,93 which in
turn might stimulate SRIH discharge via b-adrenergic
receptors.94 A direct pituitary effect of insulin is still
under debate. However, in spite of the low number of
specific insulin receptors in normal pituitary cells,95
an inhibition of GH synthesis and release, along with a
reduction of GH mRNA content in somatotropes have
been observed following exposure of these cells to
insulin in vitro.96 Insulin might also regulate GH
secretion through its effects on aminoacid metabolism
and ion transport.
Lastly, insulin may indirectly influence GH secre-
tion by inhibition of IGFBP-197 and, to a lesser
degree, of IGFBP-298 synthesis and hence by increas-
ing the levels of free plasma IGF-I which negatively
feeds back on GH secretion.
In spite of the above, the pathophysiological rele-
vance of hyperinsulinaemia in the GH hyposecretion
of obesity is challenged by the observation that GH
secretion is normal in diseases other than obesity
associated with high insulin levels99 and that in
obese subjects, normalization of serum insulin is not
followed by restoration of normal GH secretion.100
NEFA
The lipolytic action of GH has long been known. Its
administration to both animals and humans induces an
increase in serum concentrations of glycerol and
NEFA. These latter, in turn, exert a negative feedback
control on GH secretion acting at the pituitary101 and
the hypothalamus, probably by enhancing SRIH
release.102 In fact, in normal subjects, the increase in
NEFA serum concentrations blunts the somatotropin
responses to both GHRH and suprapituitary stimuli.
Based on the notion that serum levels of NEFA are
commonly elevated in obese patients,103,104 several
studies have been performed in these subjects using
acipimox, a nicotinic acid analogue, able to block
lipolysis and thus to lower serum NEFA concentra-
tions. The acute administration of this drug to obese sub-
jects has been shown to improve spontaneous and stim-
ulated (GHRH, pyridostigmine, GHRH plus pyrido-
stigmine, GHRH plus GHRP-6) GH secretion.105 – 108
Worthy of note, acipimox is able to increase the GH
response, even to the combined administration of
GHRH and GHRP-6, the most potent GH stimulus
known so far in obesity.108 The prolonged suppression
of NEFA serum levels by chronic treatment with
acipimox, further improves the somatotropin response
to the stimuli (GHRH alone and combined with
arginine).109,110
Aminoacids
GH is known to stimulate aminoacid uptake and
protein synthesis.111 In turn, aminoacids participate
in the regulation of GH release. Indeed, high protein
meals and administration of basic (arginine and
ornithine) and aromatic (tryptophan) aminoacids, sti-
mulate GH secretion in normal subjects,112,113 prob-
ably because of a decrease in hypothalamic SRIH.114
As mentioned above, an impairment of the GH
response to arginine, alone or combined with
GHRH, is well documented in obesity.12,32,33
Caloric restriction and weight loss
In obese patients, severely hypocaloric diets applied
for relatively short periods (6 weeks) and not accom-
panied by important weight losses (5.3 1.0 kg,
5.8 1.2% of initial body weight) are followed by
an evident improvement of the GH response to
GHRH,115 but not of the spontaneous hormonal secre-
tion.116 On the contrary, significant weight reduction
is associated, in these patients, with the restoration of
a normal stimulated (GHRH, insulin-induced hypo-
glycaemia, arginine, L-dopa) and spontaneous GH
secretion.22,117,118
The high GHBP levels, consistently documented in
obese subjects, normalise after significant weight loss,
whereas they are unchanged after short-term dietary
restriction.46,119 Changes in waist circumference and
abdominal sagittal diameter during weight loss were
the major determinants and accounted for 54% of the
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fall in GHBP levels in a group of obese subjects
submitted to a very low calorie diet.119
In obese patients, caloric restriction and=or weight
loss are associated with a decrease in total and free
IGF-I levels, which is much smaller than that occur-
ring in normal subjects:46,120 thus, in obesity the
production of IGF-I appears to be relatively indepen-
dent from caloric intake, provided that a sufficient
protein supply is maintained. Finally, the low IGFBP-
1 and IGFBP-2 do not display any significant increase
after weight loss with persisting hyperinsulinaemia.46
Pathophysiology of the GH-IGF-I
axis in obesity
The demonstration that drugs thought to reduce
hypothalamic SRIH release (pyridostigmine, arginine,
galanin, atenolol) improve the GH response to GHRH
in obese patients has led to the hypothesis that an
increased central SRIH tone is the cause of GH
hyposecretion in this clinical condition. This view,
however, has been challenged by the observation that,
even when SRIH secretion is suppressed by the
administration of the above mentioned drugs, the
somatotropin response to the specific releasing hor-
mone is not fully normalized. Indeed, the direct
estimation of SRIH concentrations in cerebrospinal
fluid has revealed, in a personal experience,121 that the
levels of the neuropeptide are decreased even in
morbidly obese patients compared to normal weight
subjects. This finding, which is representative of a
reduced SRIH release in the central nervous system,
may well envisage an adaptive response to the dimin-
ished secretion of GH and=or GHRH. A GHRH defect
has also been hypothesized based on the previously
mentioned low frequency of spontaneous GH secre-
tory episodes in human obesity and by several
observations in experimental animals. Genetically
obese Zucker rats are characterized by reduced
GHRH hypothalamic content and expression and, as
a likely consequence, by decreased GH pituitary
content and expression.122 – 124 However, the GHRH
defect hypothesis is challenged by the observation of
superimposable plasma and liquoral GHRH concen-
trations in obese and normalweight subjects121,125;
furthermore the plasma GHRH response to L-dopa
in obese children is normal.125 The persistence of GH
unresponsiveness to repetitive exogenous GHRH
administration is also in contrast with the hypothesis
of a hypothalamic GHRH defect, rather suggesting a
selective refractoriness of the somatotrope to the
specific hypophysiotropic peptide or a broader func-
Table 2 Hypothesized factors for the growth hormone (GH) hyposecretion in obesity
Pathogenetic factors Pros Cons
Increased central SRIH tone drugs capable of decreasing hypothalamic
SRIH secretion improve GH response to GHRH
drugs capable of decreasing hypothalamic
SRIH secretion are unable to fully normalize
the GH response to GHRH
GHRH de®ciency decreased number of GHRH peaks normal serum and cerebrospinal ¯uid
concentrations of GHRH
decreased GHRH gene expression in the genetically
obese rat
normal GHRH release in response to L-dopa
GHRP ligand de®ciency brilliant GH response to GHRPs
Somatotrope cell
insuf®ciency
lack of GH response to repeated
GHRH administration
brilliant GH response to GHRPs
Increased NEFA levels normalization of GH secretion after drug-induced
reduction of plasma NEFA concentrations
Increased free IGF-I levels elevated concentrations of plasma free IGF-I
SRIH somatostatin; GHRHGH releasing hormone; GHRPGH releasing peptide; NEFAnon esteri®ed fatty acids; IGF-I insulin-
like growth factor I.
Figure 2 Central and peripheral factors may contribute to the
growth hormone (GH) hyposecretion of obesity. Among the
hypothalamic factors, either low GH releasing hormone
(GHRH) concentrations or defective secretion of the putative
endogenous ligand for GH releasing peptides (GHRP) receptors
can be in play. The original hypothesis of somatostatin (SRIH)
hypertone has been challenged by the demonstration of low
SRIH cerebrospinal ¯uid levels in obese patients, probably the
net result of an adaptive inhibition secondary to the reduced GH
secretion and a stimulation induced by hyperinsulinaemia via b-
adrenergic receptors. The high peripheral levels of free insulin-
like growth factor-I (IGF-I) and non esteri®ed fatty acids (NEFA)
may inhibit GH release by either acting directly on the somato-
trope cells or indirectly via inhibition of GHRH and=or stimulation
of SRIH secretion. This latter might be enhanced by an insulin-
induced sympathetic hypertone. Based on animal studies
(human studies are still lacking) the high levels of leptin in
obese patients might enhance GHRH and inhibit SRIH release
and hence stimulate GH secretion; however, a condition of leptin
resistance might explain the lack of its stimulatory effect on GH
release. Finally, hypothalamic SRIH release seems selectively
refractory to stimulation by hyperglycaemia in obesity.
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tional failure of this cell. In any case, this alteration
does not appear to be irreversible, considering the
restoration of a normal GH secretion after adequate
weight loss.
Also, the marked plasma GH rise evoked by
GHRPs in obese subjects might envisage a defective
secretion of the putative endogenous ligand for GHRP
receptors, probably constituting a third hypothalamic
pathway controlling GH release.
As for the possible role of peripheral factors, the high
NEFA concentrations might be more important than
generally appreciated, since pharmacological blockade
of lipolysis is able to correct the hyposomatotropinism
of obesity. On the other side, the hypothesis of an
enhanced negative feedback by elevated IGF-I levels,
originally proposed by authors who observed a nega-
tive correlation between IGF-I and magnitude of
GHRH-induced GH rise in obese children,48 has
found new support in the recent demonstration of a
significant increase in free IGF-I concentrations in
obesity (Table 2, Figure 2).
The cause of the increased GH metabolic clear-
ance in obesity has not been clarified as yet; cer-
tainly, it is not related to a reduction of GHBP
levels, which are on the contrary frankly increased
in obese patients.
Effects of GH administration on
body composition in obesity
Caloric restriction is usually accompanied by catabo-
lism of body proteins with negative nitrogen bal-
ance.126 As a consequence, weight-reducing diets
result in loss of lean as well as fat tissue. Since
protein-supplemented diets produce only a modest
nitrogen sparing,127 the protein anabolic and lipolytic
properties of GH make this hormone a potential tool
in the treatment of obesity.
The availability of recombinant human GH (rhGH)
has encouraged a series of studies aimed at evaluating
the effectiveness of GH administration in obese
patients. In a few trials, high doses of GH have
proved capable, compared to placebo, of improving
nitrogen balance in moderately calorie-restricted
(100 kJ=kg or 75 kJ=kg ideal body weight (IBW))
obese patients.76,126 When severe caloric restriction
was applied (50 kJ=kg IBW), this effect appeared to
be dependent on the dietary carbohydrate content.128
A gradual impairment of IGF-I production in response
to exogenous GH was observed in these studies when
energy intake was progressively limited.76,126,128
These findings are not surprising when considering
the central role played by nutritional status in the
regulation of IGF-I synthesis. IGF-I plasma levels are
low in malnourished patients,120 and in normal sub-
jects fasting lowers IGF-I plasma concentrations
under basal conditions129 and in response to GH
administration.130 However, when adequate doses of
rhGH are used, significant rises in IGF-I levels occur
even in severely calorie-restricted (50 kJ=kg IBW or
1967 kJ=d) obese patients.131,132 In a personal experi-
ence,133 increase in IGF-I serum concentrations and
sparing of lean body mass (LBM) were observed after
a four-week treatment with rhGH (1 U=kg
IBW=week) of obese women undergoing severe
restriction of energy intake (41.86 kJ=kg IBW daily).
With one exception,134 the studies performed in
calorie-restricted obese patients76,126,131,132 failed to
demonstrate an enhancement of fat loss during rhGH
treatment. In contrast, a significant decrease in body
fat, especially at visceral level,135,136 is well docu-
mented in obese patients receiving GH, while on a
normocaloric diet.45,135 – 137 This finding is in line with
the reduction of body fat observed in ad libitum fed,
but not in calorie-restricted, beef steers after bovine
GH administration.138 GH treatment is known to
increase resting energy expenditure (REE), whose
main determinant is LBM, in both GH deficient
adults139 – 141 and in obese patients on a weight-main-
taining diet.137 In our experience,133 rhGH adminis-
tration was effective in preventing the diet-induced
reduction of REE and enhancing the energy metabo-
lism of LBM even in severely calorie-restricted obese
women.
Thus in a number of studies, GH administration
displayed beneficial effects on body composition in
obese patients either on weight-maintaining
diets135,137 or undergoing both moderate76,126 and
severe131,132 caloric restriction. GH administration to
obese patients appears to be a safe treatment, although
a few adverse effects have been reported in some
trials. In one study,136 50% of patients given GH
experienced signs of fluid retention, such as peripheral
oedema, muscle stiffness and arthralgia and mild
carpal tunnel syndrome. These side effects subsided
spontaneously in half of the cases and after dose
reduction in the others. In two other studies,128,131 a
rise in fasting as well as 2 h postprandial blood
glucose concentrations was observed together with
increments in fasting and postprandial serum insulin
and 24 h urinary C-peptide excretion. These altera-
tions, however, promptly disappeared when GH was
discontinued.131
On the whole, administration of rhGH at adequate
dosage appears to have beneficial effects, that is,
reduction of LBM loss and improvement of LBM
metabolic efficacy, in obese patients undergoing even
severe dietary restriction. Therefore, the effective-
ness of compounds with direct or indirect GH
mimetic activity, but less expensive than the native
hormone, seems worth investigating in obesity.
Accordingly, oral administration of the new GH
synthetic secretagogue MK-677 to obese patients
has been recently shown to increase serum levels
of GH, IGF-I and IGFBP-3, and to induce a sus-
tained increase in fat-free mass and a transient
elevation of REE.142
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Conclusions
To sum up, both spontaneous and stimulated GH
secretion, is markedly reduced in obesity. The
impaired somatotropin secretion, however, is not par-
alleled by a decrease in circulating IGF-I, whose free
fraction seems even increased, and this may account
for the normal growth of the obese child. Hypothala-
mic, pituitary and peripheral factors may contribute to
the abnormal GH secretion. A SRIH hypertone, a
GHRH deficiency or a functional failure of the soma-
totrope have been proposed with pros and cons for
each possibility. The lack of an endogenous ligand for
the recently discovered GHRP receptors is another
challenging hypothesis. On the peripheral side, the
elevated plasma levels of NEFA and free IGF-I may
play a major role. Whatever its cause, the defect of GH
secretion in obesity appears to be of a secondary
nature, probably an adaptive phenomenon, since it is
completely reversed by the normalization of body
weight.
There are experimental data suggesting a stimula-
tory influence of GH on fat cell formation in clonal
preadipocyte cell lines.143 – 145 GH may exert its adi-
pogenic effect directly by activation of protein kinase
C, leading to a rapid and transient stimulation of c-fos
gene transcription,146 or indirectly through its ability
to induce IGF-I gene expression.147,148 In obesity,
therefore, the blunted GH secretion might limit the
enlargement of the pool of adipocyte precursor cells
available for lipid deposition. Likewise, it may prevent
a further increase of the already elevated plasma
concentrations of NEFA,103,104,149 which are known
to worsen glucose metabolism.150
In spite of the above, treatment with rhGH has
consistently been shown to improve the body composi-
tion of obese patients, especially when they have been
submitted to severe hypocaloric regimens. Whether
compounds less expensive than GH and able to promote
its endogenous secretion or to mimic its effects, may be
beneficial in the therapy of weight reduction, is cur-
rently under investigation. Further studies will contri-
bute to better define the pathogenesis of the blunted GH
secretion in obesity and its possible relevance in the
development and=or maintenance of particular biologi-
cal-clinical features of obesity itself. Moreover, they
will allow a better understanding of the physiology of
GH secretion.
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